Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Merck: Regulatory Update on Cladribine Tablets
Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.
Gordon Research Conference on Synaptic Dysfunction and Neurodegeneration
Biologics-induced autoimmune diseases.
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Berlex continues legal challenge to FDA over MS drug.
Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter.
IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Interferon-β-1b: a review of its use in multiple sclerosis.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Flupirtine
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
A gender gap in autoimmunity.

Pages